Rocket Science Health, which recently partnered with Kindeva on development of its nasal delivery device, announced that the US Patent and Trademark Office (USPTO) has issued the company US Patent No. 12,343,489, titled, “Intranasal and olfactory delivery devices and methods of use.” The patent covers RSH’s nasal delivery technology, which is designed to target specific regions of the nose, particularly the olfactory cleft. According to the company, the device can handle delivery challenges such as biologics and more viscous formulations.
RSH President Sohier Hall commented, “Getting drugs to the brain is one of medicine’s hardest problems and our proprietary technology is designed to address that challenge not just for brain delivery, but also for vaccines and other treatments that need more targeted approaches. It’s not rocket science, but a simple drug delivery device that has the potential to make sophisticated drugs work, while broadening access to live-saving treatments. The granting of these key patents is an important milestone on our journey to scale and accelerate the delivery of next generation brain and central nervous system treatments, with the goal of initiating human clinical trials with our device in the near future.”
Read the Rocket Science Health press release
